Reproducibility of DXA estimations of body fat in HIV lipodystrophy: Implications for clinical research

Journal of Clinical Densitometry

Volumn 8, Issue 3, 2005, Pages 293-297

  Cavalcanti, Rodrigo B ^a,c   Cheung, Angela M ^a,c,d   Raboud, Janet ^b,c   Walmsley, Sharon ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Body fat content; Coefficient of variation; Dual energy X ray absorptiometry (DXA); HIV; Lipodystrophy; Reproducibility

Indexed keywords

ADULT; ARM; ARTICLE; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT CONTENT; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; LIPID ANALYSIS; LIPID STORAGE; MALE; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; REPRODUCIBILITY; SAMPLE SIZE; STATISTICAL ANALYSIS; WHOLE BODY AUTORADIOGRAPHY; WHOLE BODY SCANNER;

EID: 23444434113     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1385/JCD:8:3:293     Document Type: Article

References (16)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. 1999 Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353(9170):2093-2099.
2. Mallon PW, Carr A, Cooper DA. 2002 HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways. Curr Diab Rep 2(2):116-124.
3. Carr A, Samaras K, Chisholm DJ, Cooper DA. 1998 Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351(9119):1881-1883.
4. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. 2003 An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361(9359):726-735.
5. Moyle G, Carr A.2002 HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials 3(1):89-98.
6. Bodasing N, Fox R. 2003 HIV-associated lipodystrophy syndrome: assessment and management. J Infect 46(2):87-93.
7. Tsekes G, Chrysos G, Douskas G, et al. 2002 Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med 3(2):85-90.
8. Mallon PW, Miller J, Cooper DA, Carr A. 2003 Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17(7):971-979.
9. Belloso WH, Quiros RE, Ivalo SA, et al. 2003 Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients. J Acquired Immune Defic Syndrome 32(1):104-111.
10. Phillipov G, Seaborn CJ, Phillips PJ. 2001 Reproducibility of DXA: potential impact on serial measurements and misclassification of osteoporosis. Osteoporos Int 12(1):49-54.
11. Cordero-MacIntyre ZR, Peters W, Libanati CR, et al. 2002 Reproducibility of DXA in obese women. J Clin Densitom 5(1):35-44.
12. Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK. 1995 Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 5(4):262-270.
13. Bonnick SL, Miller PD.1998 Bone Densitometry in Clinical Practice: Application and Interpretation. Totowa, NJ: Humana Press.
14. Carr A, Workman C, Smith DE, et al. 2002 Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288(2):207-215.
15. McComsey G, Lonergan T, Fisher R, et al. 2002 Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV). 9th Conference on Retroviruses and Opportunistic Infection.
16. Smith DE, Hudson J, Martin A, et al. 2003 Centralized assessment of dual-energy X-ray absorptiometry (DXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials 4(1):45-49.